DRUSENoffEVO: evolution of the AREDS 2 formula, EVOlution of FORMULative technology.
DRUSENoffEVO features two important innovations in the formulation:
- EVOlution of the AREDS 2 formula.
- EVOlution in FORMULATIVE technology.
The composition retains the structure of the AREDS 2 formula, Lutein, Zeaxanthin, Vitamin E ,Vitamin C and Zinc, to which Cyanidin-3-glucoside (C3 C3G is the most representative of the anthocyanins found in many plant species As is well known these have innumerable antioxidant activities, many of which are valuable for retinal health. Black Rice contains a high concentration of Cyanidin-3-glucoside (C3G) one of the main components of anthocyanins, which may exert protective effects on apoptosis, senescence and inflammation of Retinal Pigmented Epithelium cells tissue critical for maintaining the health status of the retina and in particular the macula.
If one casts one’s mind back to today, all formulations on the market have focused on the protection of photoreceptors from photooxidation (Lutein and Zeaxanthin) and on antioxidant activity, but never specifically on the protection of the Retinal Pigmented Epithelium, except for a reported pro-metabolic activity related to Zinc as a cofactor of certain enzymes in this tissue. The formulation with C3G leads to a completion of the composition of DRUSENoffEVO precisely in reference to this aspect. The other innovation concerns the pharmaceutical technique, “New Micronization Technology.”
This technique micronizes the particle size of the active ingredients, and the smaller particle size increases the surface area in contact with the intestinal villi, increasing the absorption capacity in the digestive tract. The innovative method of tablet preparation increases the bioavailability and efficacy of the components.
An additional aspect that should not be underestimated is the role that C3G plays in visual pigment regeneration, which allows, to the extent possible, to improve a number of visual parameters such as night vision and contrast sensitivity. DRUSENoffEVO is indicated in the secondary prevention of age-related macular degeneration.